http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Crizotinib과 한방치료를 병행하여 호전된 ROS1 양성 재발성 폐암 환자 1례
장권준,양정민,이지윤,고은비,문향란,윤민지,조온유,정성헌,이범준,신광순,황우석,Jang, Kwon-jun,Yang, Jung-min,Lee, Ji-yoon,Ko, Eun-bi,Moon, Hyang-ran,Yoon, Min-ji,Jo, On-you,Jeong, Seong-heon,Lee, Beom-joon,Shin, Kwang-soon,Hwang, Woo-s 대한한방내과학회 2021 大韓韓方內科學會誌 Vol.42 No.5
Objectives: This study examined the case of a patient with ROS1-positive recurrent non-small-cell lung cancer treated with crizotinib and traditional Korean medicine. Methods: The patient was treated with crizotinib from January 20 2021 to May 22 2021, together with Haedogyangpye-tang and Haengso-tang. The tumor size was measured using computed tomography (CT), and adverse events were evaluated according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Results: After four months of combined treatment, the sizes of the lymph nodes in the porta hepatis, hepatoduodenal, retrocrural, aortocaval, and para-aortic areas had decreased, and no lymph nodes larger than 1 cm in diameter were observed. The side effects of chemotherapy also improved. Conclusions: This case study suggests that traditional Korean medicine may alleviate the side effects of chemotherapy, improve quality of life, and complement chemotherapy itself.
자궁내막암 환자의 외과적 수술 이후 발생한 후유증에 대한 한방치험 1례
고은비 ( Eun-bi Ko ),장권준 ( Kwon-jun Jang ),윤민지 ( Min-ji Yoon ),이지윤 ( Ji-yoon Lee ),양정민 ( Jung-min Yang ),오재성 ( Jae-sung Oh ) 대한한방부인과학회 2021 大韓韓方婦人科學會誌 Vol.34 No.4
Objectives: The purpose of this study is to report the effect of Korean medicine on endometrial cancer patient after laparotomy. Methods: The patient with endometrial cancer who underwent Total Abdominal Hysterectomy (TAH), Bilateral Salpingo Oophorectomy (BSO), Bilateral Paraaortic Lymph Node Dissection (BPLND) was treated by Korean medicine such as herbal medicine, acupuncture, moxibustion. To evaluate the patient, symptoms were measured by Numeric Rating Scale (NRS) and Eastern Cooperative Oncology Group (ECOG). Blood tests including cancer biomarker were conducted during treatment. Results: After treatment, postoperative pain and general weakness were gradually relieved. Conclusions: This case provides us treatment with Korean medicine have substantial benefit on postoperative complications after laparotomy.
갑상선 유두암의 외과적 절제술 이후 발생한 후유증에 대한 면역요법을 병행한 한방 치험 3례
고은비,장권준,양정민,오재성,Ko, Eun-Bi,Jang, Kwon-Jun,Yang, Jung-min,Oh, Jae-sung 대한한방내과학회 2021 大韓韓方內科學會誌 Vol.42 No.5
Objectives: This study assessed the effect of a combination of Korean medicine and immunotherapy on three papillary thyroid cancer patients following thyroidectomy. Methods: The three patients who underwent thyroidectomy received Korean medical treatments, including acupuncture, moxibustion, pharmacopuncture, and immunotherapy. To evaluate the patients, symptoms were measured using the Numerical Rating Scale (NRS) and Karnofsky Performance Status Scale (KPS). Blood tests, including thyroid function tests, were conducted during treatment. Results: After treatment, postoperative pain and general weakness were gradually alleviated. Conclusions: These cases provide evidence that treatment with a combination of Korean medicine and immunotherapy can have substantial benefits for postoperative complications following thyroidectomy.
Casodex/Nolvadex와 한방치료를 병행하여 호전된 재발성 침샘관암 환자 1례
양정민,장권준,고은비,이지윤,윤민지,조온유,정성헌,문향란,신광순,황우석,Yang, Jung-min,Jang, Kwon-jun,Ko, Eun-bi,Lee, Ji-yoon,Yoon, Min-ji,Jo, On-you,Jeong, Seong-heon,Moon, Hyang-ran,Shin, Kwang-soon,Hwang, Woo-seok 대한한방내과학회 2021 大韓韓方內科學會誌 Vol.42 No.5
Objectives: This study examined the case of a patient with recurrent salivary duct carcinoma and hepatic metastasis. Methods: The patient was treated with Casodex/Nolvadex from January 25<sup>th</sup> 2021 onward with doses of bicalutamide (150 mg/day) and tamoxifen (10 mg/day) every four weeks. Simultaneously, the patient was treated with Korean medicine. The tumor size was measured using computed tomography (CT). Adverse events were evaluated according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0. Results: Following the four-month treatment, the extent of the proximal portion of hepatic metastasis decreased, and discomfort and physical activity gradually improved. Conclusions: The results suggest that combined chemotherapy and Korean medicine may help to reduce tumor size and improve quality of life.
한방치료를 병행하여 항결핵제의 부작용을 관리한 비결핵 항산균증 환자 1례
이지윤,장권준,양정민,문향란,고은비,윤민지,조온유,정성헌,신광순,신동국,황우석,Lee, Ji-yoon,Jang, Kwon-jun,Yang, Jung-min,Moon, Hyang-ran,Ko, Eun-bi,Yoon, Min-ji,Jo, On-yu,Jeong, Seong-heon,Shin, Kwang-soon,Shin, Dong-guk,Hwang, Woo-se 대한한방내과학회 2021 大韓韓方內科學會誌 Vol.42 No.5
Objectives: This study investigated the effect of combined Korean medical treatment and antibiotics on a patient diagnosed with nontuberculous mycobacterial lung disease. Methods: The patient had been treated with antibiotics since July 2020 concurrently with Maekmoondong-tang, Banhasasim-tang, Gwakhyangjunggi-san and Bojungikgi-tang. The improvement of symptoms was evaluated using scores for the numerical rating scale (NRS), the Medical Research Council (MRC) dyspnea scale, C-reactive protein (CRP) levels, and computed tomography (CT). Results: Following treatment, the NRS, MRC dyspnea scale and CT images significantly improved. Also, CRP levels remained in the normal range during treatment. Conclusions: Traditional Korean medical treatment combined with antibiotics could be effective for treating patients with nontuberculous mycobacterial lung disease.
Epigenetic Approaches to the Treatment of Renal Cell Cancer
Seong Hwi Hong(홍성휘),Jiyoung Lee(이지영),Eun Bi Jang(장은비),Sung Yul Park(박성열),Hong-Sang Moon(문홍상),Young Eun Yoon(윤영은) 대한비뇨기종양학회 2020 대한비뇨기종양학회지 Vol.18 No.2
To summarize the epigenetics in renal cell carcinoma (RCC) and discuss the potential use of epigenetic modifiers as RCC biomarkers and treatments. Pertinent articles available on PubMed and google scholar database pertaining to kidney cancer and epigenetics were reviewed. Metastatic RCC is one of the most difficult cancers to treat. Although RCC is commonly known to be caused by VHL mutations, it is not enough to understand the complete pathophysiology of RCC. Epigenetic factors can play a fundamental role in the pathogenesis of RCC. Epigenetic regulators are classified as epigenetic writers, readers, and erasers according to their role. In this review, we discuss the potential role of epigenetic regulators as a biomarker for RCC. We also review medications that target epigenetic enzymes and are currently tried in RCC therapy.